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Metabolic syndrome (MetS) is a group of different risk factors that raises the chances of develop several 
health problems such, as cardiovascular disease and diabetes. There are few cases in literature of studies 
that specifically address the use of pharmaceutical care in MetS. The aim of study was to evaluate the 
effectiveness of home pharmaceutical interventions in patients with this syndrome. The randomized 
clinical trial was conducted in subjects with diagnosis of MetS treated in a basic unit of health from 
Cuité, Paraíba. The patients were randomized in a 1:1 ratio to two groups: intervention (IG) and control 
(CG). The IG received monthly individual pharmaceutical interventions, while the CG did not. The 
effectiveness of the intervention protocol was measured after six months, comparing the hemodynamic 
values, anthropometric, biochemistry, cardiovascular risk, medication adherence, drug related problems 
(DRP) and quality of life. The sample consisted of 63 individuals (33 IG and 30 CG) and older than 
60 years. The majority of pharmaceutical interventions were educational and/or behavioral. In the 
intervention group, significant differences were observed in the parameters systolic and diastolic blood 
pressure, triglycerides, medication adherence and DRP. The pharmaceutical interventions at home were 
effective in improving medication adherence, decreasing DRPs and helping to control components of 
the metabolic syndrome.
Uniterms: Metabolic syndrome/study. Pharmaceutical care/home. Pharmaceutical interventions. Drug 
related problems. 
INTRODUCTION
Metabolic syndrome (MetS) is a low-grade chronic 
inflammation state resulting from the interaction of 
genetic and environmental factors. MetS is constituted 
of components such as insulin resistance, atherogenic 
dyslipidemia, hypertension, central obesity, endothelial 
dysfunction, genetic susceptibility, hypercoagulable 
state and chronic stress (Kaur, 2014). Several studies 
have demonstrated the strong relationship between MetS 
and occurrence of cardiovascular diseases (CVD). MetS 
doubles the incidence of heart attack, type 2 diabetes and 
increases the risk of mortality from CVD (Grundy, 2012; 
Shin et al., 2013; O’Neill, O’Driscoll, 2015). 
The multifactorial characteristic of MetS requires 
a complex clinical management. Treatment of the MetS 
consists of healthy lifestyle (adequate diet and physical 
activity), risk factor prevention and individualized drug 
regimen. The aim is decrease the MetS´s progression, 
demanding, in most cases, polypharmacy (Kaur, 2014; 
Plaster et al., 2012). In this way, patient education through 
health professionals encourages changes in lifestyle and 
increases medications adherence (Gerstel et al., 2013). 
Pharmacist collaborates in the education process through 
guidance on the appropriate use of medicines, especially 
in primary care (Mendes, 2012, OPS/OMS, 2013; Brasil, 
2014). 
Recently in Brazil, new public policies stimulate 
the pharmaceutical action to solve problems related to the 
medicines. Inappropriate use of medications is the main 
cause of aggravation of diseases such as MetS. In view of 
this, the Federal Council of Pharmacy, through resolutions 
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585 and 586/2013, encourages the participation of 
pharmacists in multidisciplinary teams for the monitoring 
of chronic diseases, particularly in primary care (Mendes, 
2012; Brasil, 2014).
Home care is essential in the treatment of chronic 
diseases. Home pharmaceutical intervention identifies 
the main barriers to the correct use of medicines, in 
addition to collaborating with the physician increasing 
the effectiveness and safety of the medicine (Zermansky 
et al., 2006).
Meta-analysis involving 14,224 patients showed 
effectiveness of the pharmaceutical interventions related 
to health education, collaboration with the physician 
and guidance on medication use (Santschi et al., 2014). 
The blood pressure values for example, this article 
showed reductions in the order of 8.0 mmHg (systolic) 
and 4.0 mmHg (diastolic) due to the performance of the 
pharmacist. Another meta-analysis (Chisholm-Burns et 
al., 2010) concluded the pharmacist positively affects 
glycated hemoglobin values. In Brazil, a pharmaceutical 
care program significantly reduced glycated hemoglobin 
values (Mourão et al., 2013). However, the literature is 
scarce on the impact of home pharmaceutical care on 
metabolic syndrome.
Thus, the aim of this study was to evaluate the 
effectiveness of home pharmaceutical interventions in 
Brazilian primary care patients with MetS.
MATERIAL AND METHODS 
Type of study 
This is a randomized controlled study conducted 
in patients seen by primary care at Cuité city (20.312 
inhabitants), located in the northeastern Brazil. The 
study was a clinical trial with patient follow-up. These 
were recruited in first month of the study (June, 2014) 
in the main municipal unit of primary care responsible 
for more than 800 families. It was characterized as a 
pharmacotherapeutic follow-up of patients with duration 
of six months, organized with intervention and control 
group. Details of the study design, participant enrollment, 
and intervention components are described below.
Selection of patients and randomization
The study sample included patients of both genders 
aged over 18 years and diagnosed with MetS (NCEP, 2001) 
by a primary care physician in the last 30 days (June, 2014). 
Pregnant women and people with mental disorders were 
excluded from study. Were initially eligible 105 patients 
based on patient chart review; those patients who did not 
found, did not attend the blood collect for biochemical 
analysis or refused to participate of the research were 
removed. Subsequently, patients were randomized to one 
of two groups (intervention group or control group) based 
on the number assigned to their folders using the “online 
random sequence generator” (Haahr, 2014). The patients in 
the intervention group (GI) were numbered from 1 to 35 and 
36 to 65 for the control group (CG) (Adibe, Aguwa, Ukwe, 
2013). The Figure 1 shows the study design.
Data collection
For home data collection, Pharmacotherapy 
Workup Notes (Cipolle, Strand, Morley, 2004) was 
used by trained pharmacist. Demographics data (gender, 
age, income monthly/per capita and education level), 
anthropometric parameters (body mass index [BMI] and 
waist circumference), hemodynamic parameters (blood 
pressure and Framingham cardiovascular risk (D’Agostino 
et al., 2008)) and biochemical parameters (blood 
glucose and lipid profile - total cholesterol, LDL, HDL, 
triglycerides) were collected. In addition to drug-related 
problems evaluation, the Brief Medication Questionnaire 
(Ben, Neumann, Mengue, 2012) was also used to assess 
medicine compliance and WHOQOL-bref (WHOQOL, 
1995) for quality of life, both versions validated in 
portuguese. The data were collected at the beginning and 
at the end of the trial period (six months) in both groups 
(July, 2014 to December, 2014).
The study did not use sample size calculation. The 
sample was formed by all patients diagnosed with MetS 
during the period established for patient enrollment in study.
Intervention
The IG was subjected to a protocol of home visits, 
which consisted of 2 sessions of 40 minutes each (1st and 
15th days of the study) and 6 sessions of 20 minutes each 
(respectively 30, 60, 90, 120, 150 and 180 days). The 
CG had researcher visits on the 1st and on the 180th day, 
only for data collection. Blood samples for biochemical 
analysis were collected in the first and last weeks of the 
study by a pharmaceutical researcher in clinical laboratory. 
The anthropometric date and blood pressure measurements 
of patients were performed also in the first and last weeks 
of the study by pharmacist at home.
The interventions consisted of guidance to patients 
and provision of information to other health professionals, 
as needed. The patient education techniques adopted were 
delivery of an illustrated leaflet on healthy nutrition and 
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physical activity practice, disease, treatment and especially 
medicines in use information. The visits were performed 
by qualified pharmacist researcher and trained to carry out 
the proposed interventions.
In the initial visits (sections 1 and 2) were established 
the relationship with patient and information collected 
were demographic, experiences with medicines, current 
health status, medical history, nutritional status, current 
and past medications and information complementary such 
as the use of other substances, immunizations, allergies 
and alerts. With this data the drugs related problems have 
been identified (DRPs). Interventions (sections 3-8) were 
performed to resolve DRPs detected, to therapeutic targets 
and to prevent new DRPs. At the end of each session, next 
visit was scheduled in 30 days.
The patient’s interventions consisted of medication 
review, counseling on proper storage of medicines at 
home, medication education and counseling, incentive to 
medication compliance, sodium restriction, moderation 
in consumption of carbohydrates, replacement saturated 
fat and physical activity (walking in moderate rhythm 
for 30 minutes at least three times a week). Specific and 
individualized guidance for DRP resolution were provided, 
especially those related to prescriber’s contribution, 
highlighting ineffective drug therapy and untreated 
health problem. The interventions were orally conferred 
comprising the trinomial pharmaceutical-patient-
prescriber. The Pharmacotherapy Workup, developed by 
Cipolle, Strand, Morley (2004), was the clinical method 
used for the detection, planning and intervention of DRP. 
All interventions were performed by researcher, without 
institutional link with the health service.
The effectiveness of the intervention protocol was 
measured by comparing the measured values at baseline 
and after follow-up of blood pressure (BP), fasting 
glucose, total cholesterol, triglycerides, HDL cholesterol, 
LDL cholesterol, waist circumference (WC), body mass 
index (BMI), cardiovascular risk, medication adherence, 
number of DRP (including new DRP) and quality of life.
Statistical Analysis
Statistical analysis was performed using Stata 
software release 12 (Stata Corporation, College Station, 
FIGURE 1 - Flowchart of the formation of the study sample.
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TX, USA). The variables are presented as absolute and 
relative frequencies, mean and standard deviation, where 
appropriate. For comparison between CG and IG at 
baseline was used the Student t- test between the means 
and Fisher’s exact test for proportions. Each parameter was 
analyzed by multiple regression of the differences between 
initial and final values of each group, being the initial 
parameter values adjusted for control of confounding. 
Significance was set asp < 0.05.
Ethical approval
The study was approved by the Research and Ethics 
Committee of the State University of Paraiba, protocol 
number 31028914.2.0000.5187/14.
RESULTS
In baseline, there were no statistically differences 
between the groups (CG vs IG) in relation to demographic, 
biochemical, hemodynamic and anthropometric 
characteristics. Likewise, medication compliance, quality 
of life and cardiovascular risk. The sample consisted of 
63 subjects with a median age of 62 years (IG) and 68 
years (CG). There was a predominance of females, in both 
groups, 26 women (79.8%) in the intervention group and 
22 (73.3%) in the control group (Table I).
Clinical characteristics (Table I) and therapeutic 
profile (Table II) showed no differences between groups 
at baseline, except for the slightly higher DRP mean 
in the GI (reflection of relatively small sample size). 
TABLE I - Baseline demographic and clinical characteristics of the studied patients in the control and intervention groups, n (%), 
mean ± S.D.
Variable Control group Intervention group p
Patients (n) 30 33 -
Male:Female 8 (26.7%):22 (73.3%) 7 (21.2%):26 (79.8%) 0.800
Age (years) 66.9 +/- 9.7 (43 - 82) 61.4 +/- 12.2 (39 - 80) 0.056
BMI (Kg/m2) 26.5 +/- 4.2 (16.2 - 34.4) 28.5 +/- 4.0 (21.9 - 38.4) 0.061
Waist circumference 98.1 +/- 8.2 (79 - 118) 101.3 +/- 8.5 (87 - 120) 0.133
Framingham 10-year CHD risk 20.4 +/- 8.4 (5.3 - 30) 17.8 +/- 9.2 (2 - 30) 0.328
Monthly household income ($) 325.8 +/- 142.5 (203.6 - 814.4) 366.2 +/- 142.5 (203.6 - 610.8) 0.575
Per capita monthly household income ($) 101.8 +/- 20.4 (40.7 - 407.2) 122.2 +/- 20.4 (40.7 - 305.4) 0.607
Level of education
No formal education 11 (36.7%) 12 (36.4%) 0.841
Primary education level 19 (63.3%) 18 (54.5%) 0.611
Secondary education level 0 3 (9.1%) 0.101
SBP (mmHg) 135.5 +/- 20.4 (110 - 200) 142.6 +/- 14.6 (120 - 170) 0.134
DBP (mmHg) 80.2 +/- 10.0 (60 - 100) 85.3 +/- 10.1 (70 - 110) 0.056
Fasting glycemia (mg/dL) 98.3 +/- 33.6 (70 - 218) 114.1 +/- 54.2 (77 - 311) 0.171
Total cholesterol (mg/dL) 188.6 +/- 40.6 (120 - 269) 180.8 +/- 42.9 (128 - 377) 0.455
LDL-C (mg/dL) 107.2 +/- 36.0 (47 - 175) 91.2 +/- 35.9 (47 - 175) 0.455
HDL-C (mg/dL) 42.9 +/- 12.8 (28 - 79) 44.7 +/- 13.0 (20 - 85) 0.018
Triglycerides (mg/dL) 199.4 +/- 85.4 (61 - 473) 225.6 +/- 102.3 (96 - 618) 0.270
Brief Medication Questionnaire Adherence Scale 15 (50%) 16 (48.5%) 0.869
High 3 (10%) 4 (12.1%)
Medium 12 (40%) 12 (36.4%)
Low 15 (50%) 17 (51.5%)
Quality of Life 64.7 +/- 7.8 (47.2 - 77.3) 63.7 +/- 7.2 (47.2 - 75.1) 0.591
S.D Standard deviation. BMI body mass index; CHD coronary heart disease; LDL-C low-density lipoprotein cholesterol; HDL-C 
high-density lipoprotein cholesterol; SBP systolic blood pressure; DBP diastolic blood pressure.
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DRP´s compliance prevailed over effectiveness and 
indication. 
At baseline, IG presented 27 patients (81.8%) 
with one or more DRP and 6 patients (18.2%) without 
DRP. After 6 month follow-up, 21 patients (63.6%) still 
presented DRP, considering the unresolved and/or news 
cases and 12 patients (36.4%) without DRP. The CG 
remained stable at baseline and after follow-up: 19 patients 
(63.3%) with DRP and 11 patients (36.7%) without; 
20 patients (66.7%) with DRP and 10 patients (33.3%) 
without DRP, respectively.
Aiming to solve the DRP found and prevent 
future DRP, 76 pharmaceutical interventions (PI) were 
performed. Of these PIs, 49 (64.5%) were related to 
conduct on educational and behavioral: medication 
management (medication review of patient, assessment 
of medication compliance, orientation about appropriate 
storage of medicines at home); educational interventions 
to patients (education and counseling about medications, 
lifestyle, physical activity and compliance); distribution 
of educational booklet about healthy food. Twenty PI 
(26.3%) involved the physician requesting reassessment 
of therapy, replacement and/or addition of medication. The 
referral for clinical evaluation of potential untreated health 
problem occurred in 7 situations (9.2%). Interventions 
directed at the IG totaled an average of 2.3/patient. 
Interventions performed with the physician showed an 
acceptance of 63% (n=17), acceptability of the patient was 
not measured to not interfere in methodology.
Table III depicts the effectiveness of PI in improving 
biochemical and hemodynamic profiles, medication 
compliance, quality of life and the mean DRP at baseline 
and follow-up. In IG, there were significant differences 
(p <0.05) in systolic blood pressure (p = 0.003), diastolic 
blood pressure (p = 0.043), triglycerides (p = 0.034), 
adherence (p = 0.026) and DRP (p = 0.001). The control 
group in turn, showed similar values in both moments, 
without significant differences in all parameters.
TABLE II - Initial therapeutic profile and DRP of control and intervention group, n (%), mean ± S.D.
Variable Control group Intervention group p
Medications numbers 3.2 +/- 1.7 (1 - 7) 4.1 +/- 1.9 (0 - 8) 0.055
Anatomical Therapeutic Chemical Code
C10A - Lipid modifying agents, Plain 20 (20.85) 31 (21.8%) 0.874
C03A - Low-ceiling diuretics, Thiazides 13 (13.5%) 10 (7.0%) 0.118
A10B - Blood glucose lowering drugs, excl. Insulins 10 (10.4%) 20 (14.1%) 0.434
C09A - ACE inhibitors, Plain 9 (9.4%) 11 (7.8%) 0.646
C09C - Angiotensin II antagonists, Plain 9 (9.4%) 10 (7.0%) 0.627
M01A - Antiinflammatory and antirheumatic products, Non-
steroids
5 (5.2%) 3 (2.1%) 0.274
A02B - Drugs for peptic ulcer and gastro-esophageal reflux 
disease
3 (3.1%) 10 (7.0%) 0.251
Others 27 (28.1%) 47 (33.1%) 0.476
Total 96 (100%) 142 (100%) -
Drug-related problems (DRP) 1.0 +/- 1.2 (0 - 4) 2.2 +/- 1.5 (0 - 5) 0.004
Categories of DRP
The patient forgets to take the medication (Adherence) 8 (25.8%) 9 (12.3%) 0.162
Requires additional pharmacotherapy to attain synergistic or 
additive effects (Indication)
6 (19.4%) 7 (9.6%) 0.337
Inappropriate frequency resulting in low dose (Effectiveness) 3 (9.7%) 8 (10.9%) 1
The problem is refractory to the drug product (Effectiveness) 2 (6.5%) 11 (15.1%) 0.214
The patient prefers not to take the medication (Adherence) 2 (6.5%) 7 (9.6%) 0.714
A medical condition requires the initiation of drug therapy 
(Indication)
2 (6.5%) 7 (9.6%) 0.714
Others 8 (25.8%) 24 (32.9%) 0.213
Total 31 (100%) 73 (100%) -
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DISCUSSION
As evidenced, the results of this study confirm the 
efficacy of pharmaceutical interventions at home in the 
control of lipid and blood pressure levels in patients with 
MetS. We observed in IG that the increase in medication 
compliance implies to decrease in mean of DRP. This 
result is similar to that reported by other authors who 
showed pharmaceutical interventions as beneficial for 
blood pressure and triglycerides (Santsch et al., 2011; 
Santsch et al., 2012; Charrois et al., 2012; Cheema, 
Sutcliffe, Singer, 2014; Wal et al., 2013; Firmino et 
al., 2015). However, these studies have been limited a 
hypertension and diabetes, MetS is rarely investigated. 
Besides, the methodology did not consider home 
interventions. The merit of this study is identification, 
monitoring and education of patients with MetS. We 
using a broad approach, contrasting to pharmaceutical 
care protocols restricted to hypertension, diabetes and 
dyslipidemia.
The homecare services are a valid strategy for the 
monitoring of chronic diseases through identification 
of DRP and adverse reactions, improvement in lipid 
profiles, blood pressure and quality of life (Peterson et al., 
2004; Sino et al., 2013). The MetS is characterized as a 
complex disorder whose diagnosis is not well established 
and treatment does not integrate conventional care 
protocols (Hammad et al., 2011). The literature is scarce 
about the role of home pharmaceutical service in the 
treatment of patients with MetS, although some studies 
suggest benefits when isolated syndrome components 
were approached. The homecare program developed by 
Peterson and collaborators (2004) has been successful 
in reducing total cholesterol in dyslipidemic patients. 
This study concluded that pharmacists are important to 
detection and prevention of low compliance. Patients 
are made aware benefits of diet and lifestyle changes; 
as well stimulate use of lipid-lowering drug therapy and 
adequate follow-up.
Most of interventions performed involved education 
and stimulation of medicine compliance, which increased 
at end of the study. The predominant DRP in both groups 
involves forgetting or misuse of medication because 
misconception of the prescription; in others words, 
absence of medication compliance. As half of the patients 
were categorized as non-adherent to medication treatment, 
the prevalence of DRP related to adherence is well 
established. Estimated that non-medication adherence 
is responsible for 10% of hospital admissions for 
hypertension and diabetes, besides causingmajor spending 
on health, worsening in quality of life and prognosis of 
these diseases (Russel, Conn, Jantarakupt, 2006; Jin et 
al., 2008; Doggrell, 2010). Some factors present in this 
sample are commonly associated with low medication 
TABLE III - Comparison of parameters at baseline and after 6 month follow-up, n (%), mean ± S.D.
Variable
Control group Intervention group
Baseline 6 months p Baseline 6 months p
BMI (Kg/m2) 26.5+/- 4.2 25.9 +/- 6.4 0.484 28.5 +/- 4.0 28.7+/- 4.1 0,091
Waist circumference 98.1 +/- 8.2 98.5 +/- 8.5 0.093 101.3 +/- 8.5 101.5 +/- 8.9 0.699
Framingham 10-year CHD risk 20.4 +/- 8.4 22.0 +/- 8.0 0.106 17.8 +/- 9.2 16.3 +/- 8.9 0.081
SBP (mmHg) 135.5 +/- 20.4 141.3 +/- 21.5 0.285 142.6 +/- 14.6 131.2 +/- 19.1 0.003
DBP (mmHg) 80.2 +/- 10.0 86.0 +/- 13.1 0.06 85.3 +/- 10.1 81.4 +/- 9.4 0.043
Fasting glycemia (mg/dL) 98.3 +/- 33.6 113.2 +/- 39.8 0.122 114.1 +/- 54.2 106.6 +/- 31.9 0.482
Total cholesterol (mg/dL) 188.6 +/- 40.6 185.0 +/- 43.0 0.584 180.8 +/- 42.9 189.2 +/- 32.4 0.271
LDL-C (mg/dL) 107.2 +/- 36.0 104.1 +/- 33.7 0.601 91.2 +/- 25.2 102.1 +/- 27.0 0.0717
HDL-C (mg/dL) 42.9 +/- 12.8 39.7 +/- 12.6 0.327 44.7 +/- 13.0 50.0 +/- 28.6 0.096
Triglycerides (mg/dL) 199.4 +/- 85.4 221.1 +/- 85.9 0.329 225.6 +/- 102.3 183.4 +/- 52.4 0.034
Brief Medication Questionnaire 
adherence scale
15 (50%) 14 (46.7%) 0.717 16 (48.5%) 22 (66.7%) 0.026
Quality of Life 64.7 +/- 7.8 64.9 +/- 7.7 0.927 63.7 +/- 7.2 64.5 +/- 7.0 0.634
DRP 1.0 +/- 1.2 1.1 +/- 1.3 0.752 2.2 +/- 1.5 0.9 +/- 1.0 0.001
Medications numbers 3.2 +/- 1.7 3.1 +/- 1.8 0.828 4.1 +/- 1.9 3.7 +/- 1.6 0.340
DRP Drug-related problems.
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adherence as aging, poor education and income. Some of 
these factors, especially aging and poor education make 
it difficult to understand written or oral explanations. As 
noted in our study, brief home explanations are effective 
in reducing this deficiency. 
During the visits, the on-site observation of the 
medicines was evidenced for a better orientation related 
to the use and storage. The accumulation of home 
medications may be associated with worse clinical 
outcomes and lower adherence to treatment (Sorensen et 
al., 2005), as well as higher frequency of self-medication, 
administration errors, drug interactions and adverse 
reactions (Wieczorkiewicz, Kassamali, Danziger, 2013; 
Ocan et al., 2014). For example, it was common in this 
sample a bad organization of home stock, difficulties in 
the identification of drugs and their dosage, especially 
due advanced age and low education. Often, the patient 
referred the product by color and size, but could not 
remember the name of the active ingredient or its 
therapeutic indication. Observed that the orientation 
about schedules and appropriate use of medications was 
facilitated with the product in hands, likewise that was 
possible to demonstrate the local and the appropriate 
organization of medications at home.
Observations of health professionals in the home 
environment can provide important contextual details that 
help understand the problems and how can be solved. The 
interventions can be developed, considering the individual 
limitation, and integrated with successfully in home 
(Gilmartin, 2013). 
Improving medication adherence not equally 
reflected in all parameters. Some components of MetS 
are more susceptible to pharmaceutical interventions 
such as blood pressure and triglyceride levels, because 
they respond more rapidly to pharmacotherapy. Reducing 
waist circumference, fasting glucose and HDL cholesterol 
require more pronounced changes in lifestyle and dietetics 
habits, demanding a response time higher than a six-month 
follow-up (Hammad et al., 2011). Thus, the resolution of 
problems related to medication adherence directly affects 
the reduction of specific parameters. 
An important aspect of this study was the relatively 
short time taken in the interventions. After the first two 
meetings of about 40 minutes and dedicated to data 
collection, short subsequent meetings (20 minutes) every 
30 days were sufficient to promote improvements some 
parameters.
However the study has some limitations, mainly 
related to the small sample size and a short-term follow-
up. The sample size may decrease the effectiveness 
in detecting differences between the groups and the 
generalization can be restricted to patients with advanced 
age, low income and education. Therefore, longer studies 
and larger numbers of patients are necessary to evaluate 
the long-term benefits in other populations.
CONCLUSIONS
The results obtained in this study showed that the 
pharmaceutical interventions in the home environment 
were effective, resulting in increased medication 
adherence (18.2% increase) and decreased DRP mean in 
the sample (59.0% decrease), as well as reduction of blood 
pressure (8.0%) and serum triglycerides (18.7%).
The strategy education pharmaceutical centered 
in the home orientation establish a pharmacist-patient-
medication relationship. This relationship stimulates 
self-care both in relation to medicine and non-medicine 
treatment. Benefits of an appropriate pharmaceutical 
orientation are diverse: patients can recognize the need 
to medicines to maintain their health and well-being, 
the interaction between health professional and patient 
becomes more dynamic by establishing an environment of 
trust, capable to increase adherence to treatment (Andrade, 
Silva, Freitas, 2004). 
Also is evident the importance of a multidisciplinary 
team committed with integral care and observing the 
individuality of each patient, because when performs 
interventions according to their skills and knowledge can 
generate results even more satisfactory.
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